Please assess the completion status of the following clinical trial:

Trial Title: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be able to provide informed consent according to institutional guidelines~* Patients must have: 1) MCL; or 2) relapsed or refractory cluster of differentiation (CD)20 positive B-cell indolent NHL; or 3) relapsed CLL~* Patients must have measurable disease/disease status requirements as follows:~* For CLL patients, symptomatic disease as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria that mandate treatment~* For B-cell NHL patients must have at least one of the following to be eligible:~  * Positron emission tomography (PET) avid or measurable disease by computed tomography (CT) scan defined as at least 1 lesion that measures \> 2 cm in a single dimension~ * Significant bone marrow and/or peripheral blood involvement by NHL (i.e. leukemic phase) as determined by the investigator~ * Patients with Waldenström macroglobulinemia (WM) are exempt from this requirement if they have symptomatic hyperviscosity or clinically relevant cytopenias and elevated serum immunoglobulin M (IgM)~* Patients must have adequate bone marrow reserve as indicated by an absolute neutrophil count (ANC) \> 1.500/mm\^3 and platelet count \> 150.000/mm\^3 if no bone marrow involvement; however, if there is significant lymphoma/leukemia bone marrow infiltration, no pre-existing hematologic parameters must be met~* Patients must have a performance status of 0, 1, or 2 according to Eastern Cooperative Oncology Group~* Serum creatinine \< 2.0 mg/dL or estimated glomerular filtration rate (GFR) \> 60 mL/min~* Serum bilirubin =\< 1.5 × upper limit of normal (ULN)~* Aspartate transaminase (AST)/alanine transaminase (ALT) =\< 2.5 × ULN~* Alkaline phosphatase =\< 2.5 × ULN~* Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment~* Male and female patients must agree to use an effective contraceptive method during the study and for a minimum of 6 months after study treatment~Exclusion Criteria:~* Significant hypersensitivity to cladribine or vorinostat; hypersensitivity to rituximab infusion is not an exclusion criterion; however, appropriate changes to infusion schedules will be made based on current or prior reactions~* Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol~* Patients with a diagnosis of a relapsed/refractory aggressive cluster of differentiation antigen 20 (CD20)+ B-cell neoplasm defined as Burkitt's lymphoma or diffuse large B-cell lymphoma~* A diagnosis of acute lymphoplasmic leukemia, and lymphoblastic lymphoma~* Use of investigational agents or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea and steroids; the patient must have recovered from all acute toxicities from any previous therapy~* Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment~* Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)~* Pregnant or lactating patients~* Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results~* Patients with acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV) associated complex are not eligible for treatment~* Patients with active hepatitis B or C are not eligible for the study~* Patients taking other histone deacetylases (HDAC) inhibitors; for example, patients taking valproic acid, there must be a 14 day washout period prior to enrollment in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Previously untreated (Type: EXPERIMENTAL): Patients enrolled with untreated, newly diagnosed mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) \[Group I\].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- Relapsed (Type: EXPERIMENTAL): Patients with relapsed disease including indolent Non-Hodgkins Lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) \[Group II\].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete